Can You Take Wegovy If You Have Had Pancreatitis?

Why does a history of pancreatitis matter when considering Wegovy?

Pancreatitis is inflammation of the pancreas, and a previous episode leaves the organ more vulnerable. The pancreas plays a central role in digestion and blood-sugar control, and GLP-1 medicines like semaglutide interact with pathways that touch both functions. That interaction is not the same as causing harm in everyone, but regulators have been clear that the risk of acute pancreatitis exists with this class of drug.

In January 2026, the MHRA issued a formal Drug Safety Update covering GLP-1 receptor agonists. It confirmed acute pancreatitis as a recognised, if uncommon, adverse effect and reinforced the importance of telling your prescriber about any relevant medical history before starting treatment. You can read that communication through the MHRA Drug Safety Updates archive on GOV.UK.

The Wegovy SmPC, published on the electronic Medicines Compendium, describes pancreatitis as a known undesirable effect and cautions that treatment should not be started in someone with a history of pancreatitis without careful evaluation. That is the manufacturer's own position, endorsed by the regulator. For the full prescribing detail, the Wegovy SmPC on the eMC is the authoritative source. At nume (no, at nume) our prescribers work from these documents, not from assumptions.

The short answer, then: a previous episode of pancreatitis does not automatically make Wegovy impossible, but it makes clinical scrutiny essential. Many people with this history will be advised to explore other options.

What do prescribers look at when pancreatitis is in your history?

Not all pancreatitis is the same. A single mild episode caused by gallstones in your twenties, successfully treated and fully resolved, tells a different story to recurrent acute pancreatitis, chronic pancreatitis, or an episode of unknown cause.

A prescriber considering Wegovy for someone with a past episode will typically want to understand: what triggered it, how severe it was, whether the underlying cause has been addressed, how long ago it occurred, and whether the pancreas has recovered fully. They will also weigh the seriousness of your current weight-related health conditions against the added risk. This is not a tick-box exercise, it is clinical reasoning.

The overview of Wegovy as a treatment explains the broader eligibility picture for people without this kind of history. If you do have it, that standard picture changes, and the right answer can only come from a clinician with access to your notes. Our prescribers ask about pancreatitis specifically during the consultation, and will be direct about whether semaglutide is appropriate for you.

If there is genuine uncertainty, they may recommend you involve your GP or gastroenterologist before starting any GLP-1 medicine. That is not a delay tactic; it is the right call.

When should you seek medical help if you are already on Wegovy?

This question matters even for people without a prior history, but it is especially urgent if you have had pancreatitis before. The warning sign to act on is severe abdominal pain that does not ease and may radiate through to your back. It can occur with or without vomiting.

Do not wait until your next routine call with a prescriber. If that pain starts, get medical attention the same day. In a serious case, call 999 or go to A&E. This is the guidance from the NHS patient information page for semaglutide, and it applies regardless of whether your pancreatitis was diagnosed years ago or never at all.

Other side effects worth knowing are covered on our Wegovy side effects page, including the full gastrointestinal profile (nausea, loose stools, constipation, reflux) that most people experience to some degree in the early weeks of treatment.

If you suspect a side effect from Wegovy, you can report it directly to the MHRA through the Yellow Card scheme. That reporting is voluntary but valuable, it is how regulators spot patterns that lead to updates like the January 2026 communication.

Is there a safer GLP-1 option if Wegovy is ruled out?

If a prescriber decides semaglutide is not appropriate given your history, it does not necessarily mean all weight-management medicines are off the table. Tirzepatide (Mounjaro), a dual GIP and GLP-1 receptor agonist, carries its own pancreatitis caution and would face the same careful assessment. Neither is a safe workaround for the other.

What changes is the risk-benefit calculation, which varies from person to person. Some people with a remote, well-resolved history of pancreatitis are considered for GLP-1 treatment under close monitoring. Others are not. The practical guidance on reducing pancreatitis risk during Wegovy treatment is useful reading if you proceed, but it does not replace the prescriber's assessment of whether you should start at all.

You can find out more about the connection between this class of medicine and pancreatic inflammation on our dedicated Wegovy and pancreatitis page. For questions about the timeline (how early in treatment the risk is highest) our page on how quickly pancreatitis can occur with Wegovy covers what is currently understood.

If you are unsure where you stand, the most useful next step is a consultation. Speak to our prescribers, they will give you a direct answer based on your actual history, not a generic one. If you are moving up to a higher dose and want to know what to expect, our page covering the side effects associated with the Wegovy 1ml dose is worth reading before your next injection.